On Thursday, 04 September 2025, Akebia Therapeutics (NASDAQ:AKBA) presented at the Wells Fargo 20th Annual Healthcare Conference 2025, showcasing its strategic initiatives and financial health. The company highlighted the commercial success of VAFSIA, a promising treatment for anemia in dialysis patients, while also addressing challenges such as the loss of IP exclusivity for Auryxia. Akebia’s focus on expanding its pipeline and securing market access demonstrates its commitment to becoming a leader in renal healthcare.
Key Takeaways
- VAFSIA, targeting anemia in dialysis patients, represents a billion-dollar market opportunity.
- Akebia plans a Phase III trial for VAFSIA in non-dialysis CKD patients, a multi-billion dollar opportunity.
- Auryxia generated $47 million in Q2, despite losing IP exclusivity.
- Akebia ended Q2 with $137 million in cash, aiming for profitability.
- The VOICE study is fully enrolled, with results expected in early 2027.
Financial Results
Akebia’s financial performance in Q2 2025 was marked by:
- Auryxia revenue of $47 million, maintaining growth despite IP challenges.
- VAFSIA revenue of $13.3 million, reflecting successful market penetration.
- A robust cash position of $137 million, supporting strategic initiatives.
Operational Updates
VAFSIA’s market presence is expanding, with:
- An increase in prescribers from 640 in Q1 to 725 in Q2.
- Average prescriptions per prescriber rising from 12 in Q1 to over 13 in Q2.
- DaVita’s operational pilot involving over 100 clinics, with full access anticipated for its 200,000 patients.
- Strategic partnerships with US Renal Care, IRC, and DCI to enhance prescribing access.
- Future Outlook
Akebia’s strategic objectives for the remainder of 2025 include:
- Continuing the U.S. launch of VAFSIA.
- Initiating the VALOR Phase III trial for non-dialysis CKD patients.
- Advancing pipeline projects like AKB-9090 for acute kidney injury.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.